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SUMMARY 
The current treatment for critical-sized boned defects, bone morphogenetic protein 2 
(BMP-2) loaded collagen sponge grafting, is often inadequate for composite bone-muscle defects, 
which heal more slowly with higher rates of non- or malunion. Due the additional muscle defect, 
there is a vacancy of vasculature around the bone defect, causing insufficient nutrient and cytokine 
delivery and thus hindering bone regeneration. Hypothesizing that increasing angiogenesis will 
improve regeneration, we have previously proposed to co-deliver microvascular fragments (MVF) 
or stromal vascular fraction (SVF), which have been shown to mature into microvascular networks 
in vitro and in vivo, with BMP-2 in a collagen sponge. However, in preliminary studies, collagen 
sponge co-loaded with BMP-2 and MVF showed augmented release of BMP-2 compared to those 
co-loaded with SVF or with BMP-2 only. Although they are both derived from the same adipose 
tissue source, we hypothesize that their cellular composition may differ and thus affect BMP-2 
kinetics. Therefore, this project aims to characterize the cellular components of MVF and SVF 
using flow cytometry to elucidate the potential mechanism of differential BMP-2 release. It was 
found that MVF has a relatively lower percentage of mesenchymal stem cells (MSCs) and 
relatively higher percentage of mature endothelial cells (ECs) than SVF, suggesting a role for ECs 
in the augmented BMP-2 release from MVF-loaded collagen sponges.   
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CHAPTER 1 
INTRODUCTION AND LITERATURE REIVEW 
Bone can spontaneously heal and restore function and is one of the few organs in the body 
that does not undergo scarring1. However, this mechanism is inadequate when dealing with critical 
sized bone defects. A critical sized bone defect is defined as an orthotopic defect that will not heal 
within the lifespan of the animal without intervention. Critical sized bone defects can arise from 
congenital defects, trauma, and tumor excision2. Despite their prevalence and numerous clinically 
available approaches, effectively treating critical sized bone defects remains a challenge.   
Bone grafting, surgical replacement of a missing bone segment with autogenic, allogenic 
or xenogenic material to restore its function, was the first treatment strategy utilized. Since the 
discovery of bone’s osteoinductive capacity from its own demineralized, devitalized matrix in 
1965, bioactive proteins, majorly cytokines, have been intensively researched for bone tissue 
regeneration purposes1, 3, 4. Bone morphogenetic protein 2 (BMP-2), one of the most studied 
cytokines involved in bone regeneration, is a cytokine of the transforming growth factor beta 
(TGF-β) superfamily. It is naturally produced by osteoprogenitor cells, osteoblasts, and bone 
extracellular matrix (ECM) and is involved in promoting differentiation of osteoblasts from 
osteoprogenitor and mesenchymal cells5. Since the recent FDA approval, recombinant human bone 
morphogenetic protein 2 (rhBMP-2) loaded in collagen sponge has been utilized to treat critical 
sized bone defects6, 7. Although this treatment has shown great efficacy compared to bone grafting 
alone, a high dosage of BMP-2 is required, and the mechanical performance of the regenerated 
bones do not match that of native bone tissue. Furthermore, high doses of BMP-2 can cause side 
effects such as cyst-like ectopic bone formation and soft tissue swelling8. Different BMP-2 
delivery methods and grafting materials have been tested to achieve a better therapeutic outcome1, 
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9. However, due to the lack of vascularization, the cells within large bone defects face inevitable 
death because of the lack of oxygen and other nutrients, thus hindering the clinical outcome of the 
BMP-2 treatment.  
Muscle defects are almost always present along with critical sized bone defects. Not only 
does this affect the mechanical performance of the injured bone, but the missing vasculature 
resulting from the missing muscle also greatly hinders bone regeneration. It has been shown that 
even subtle reductions in bloodflow within the healing callus negatively influence the mechanical 
properties of the healing bone10. Thus, reconstructing an effective transportation system along with 
promoting osteogenesis is essential in treating critical sized bone defects. Current strategies of 
promoting vascularization include administering related growth factors, which are complicated by 
undesirable side effects and difficulties in cytokine delivery10. Other approaches involve 
implanting a pre-vascularized construct, where an initial vascular network is established in vitro 
by seeding a single cell type, or a combination of several cell types (mesenchymal stem cells, 
endothelial cells, etc.) into scaffolds for implantation into the injury site to promote the rapid 
reestablishment of vasculature11-13. Microvascular fragments (MVF) are a multicellular vascular 
construct obtained from adipose tissue. Stromal vascular fraction (SVF) is a single cell level 
population that consists of multiple cell types, including endothelial, muscle, stem and other cell 
types, that is also obtained from adipose tissue. It has been shown that MVF can elongate in 
collagen gel in vitro, and transplanted MVF can rapidly develop into blood-perfused networks in 
vivo14, 15. Rather than seeding a single cell type, seeding MVF or SVF can potentially be more 
efficient, as they tend to inosculate more quickly and form more mature vessels. Both MVF and 
SVF can be isolated from adipose tissue, thus enabling autologous use. Additionally, MVFs and 
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SVFs may be rich sources of mesenchymal stem cells, which makes them promising candidates in 
the context of bone regeneration15. 
We propose to use a BMP-2 loaded collagen sponged seeded with MVF or SVF (figure 1) 
as a more effective strategy for treating critical-sized bone-muscle composite defects. The BMP-
2 serves to promote osteogenesis, while MVF and SVF further enhance the therapeutic effect by 
providing the vasculature critical to bone regeneration. Previous research done toward this project 
revealed a difference in the BMP-2 release profile of BMP-2 loaded collagen sponges seeded with 
MVF and SVF. BMP-2 loaded collagen sponges seeded with MVF showed a greater release of 
BMP-2 than those of acellular or SVF seeded sponges. We aim to uncover the cause of this 
different BMP-2 release profile, which may augment our treatment strategy, by characterizing the 
cellular components of SVF and MVF using flow cytometry.  
 
Figure 1 Schematics of BMP-2 and MVF/SVF loaded collagen sponge (not to scale) 
It was hypothesized that mesenchymal stem cells (MSC), pericytes, mature endothelial 
cells (EC), EC progenitors, and smooth muscle cells (SMC) are present in both MVF and SVF but 
that their relative proportions may differ, thus enabling different cellular interactions with BMP-2 
between the two groups. More specifically, a higher proportion of MSCs present in MVF was 
hypothesized to be the main cause of this increased BMP-2 release through MSC-BMP-2 
interactions. 
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CHAPTER 2 
METHODS AND MATERIALS 
2.1 MVF isolation from adipose tissue 
Epididymal fats were harvested from male retired breeder rats under isoflurane induced 
anesthesia. The fat was placed in a tube with HBSS with 5% FBS. Fat pads were manually minced 
for 7-8 minutes until a homogenous mixture was obtained. Minced adipose tissue was then 
chemically digested (per mL fat: 1.5 mL PBS (Sigma Aldrich), 0.75 g BSA (Sigma Aldrich), 2 mg 
DNase (Sigma Aldrich), 3.5 mg collagenase (Worthington)) with agitation at 37 °C. Digestion was 
stopped by adding serum-containing HBSS at a minimum 1:1 volumetric ratio. The digested 
solution was then centrifuged at 4000 rpm for 4 minutes in 50 mL conical tubes to allow removal 
of fat globules. The vascular pellet was then washed and resuspended in FBS-HBSS and 
centrifuged at 3000 rpm for 3 minutes in 15 mL conical tubes twice. Pellets were re-suspended in 
BSA-PBS and filtered first through a 200 μm nylon filter to remove residual large tissue pieces, 
then through a 20 μm filter membrane to remove single cells. MVF were collected by washing the 
20 μm membrane with 40 – 50mL FBS-HBSS solutions (Figure 2)14.  
 
2.2 SVF isolation from adipose tissue 
The procedure for SVF isolation is similar to that of MVF, but the chemical digestion was 
done on a shaker at 225 rpm at 37°C for 30 minutes in order to break down the vascular 
components to the single cell level.  SVF was filtered in the same manner as MVF; however, the 
flow-through passing the 20μm filter was collected as single cell SVF. 
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          Figure 2. Schematic of SVF isolation 
 
2.3 Panel selection  
The cell populations of interest are MSCs, pericytes, mature and progenitor ECs, and SMCs. While 
red blood cells (RBC) are present, they were not examined in this study; thus, they were eliminated 
during cell preparation. A panel of MSC markers (CD29+CD90+CD45-) was selected from MSC 
markers commonly used in previously published literature 16-18. Both pericytes and SMCs express 
alpha smooth muscle actin (ASMA), but NG2 expression is exclusive to pericytes. CD31 is a 
common marker for EC and is shared by pericytes. EC progenitors also express CD34; however, 
as EC mature, CD34 expression is lost18. Thus, the remaining four populations were classified as 
pericytes (ASMA+NG2+CD31+), SMCs (ASMA+NG2-CD31-CD34-), mature ECs (ASMA-
NG2-CD31+CD34-), and EC progenitors (ASMA-NG2-CD31+CD34-). 
  The seven markers chosen were divided into two panels to be prepared and analyzed 
separately in order to minimize the spectral overlap between the channels. MSCs were identified 
in panel 1, while both mature and progenitor endothelial cells, pericytes, and smooth muscle cells 
were identified in panel 2. All antibodies used were fluorochrome conjugated, and the 
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combinations of fluorochromes in each panel were selected with the assistance of Fluorescence 
Spectrum Viewer from BD Bioscience to ensure minimal spectral overlap. Table 2 summarizes 
the antibodies used in each panel19, 20.  
Table 1.  Cell population classifications for pericytes, EC (mature and progenitor) and SMC. 
 Pericytes EC (mature) EC (progenitor) SMC 
ASMA + - - + 
NG2 + - - - 
CD31 - + + - 
CD34 / - + - 
 
2.4 Cell preparation   
 After MVF and SVF collection, the cells were incubated in 6 mL of 1X RBC lysis buffer 
for 5 minutes to remove red blood cells. The cells were then divided into single stain control, 
fluorescence minus one (FMO) control, and experimental groups. Detailed staining protocols for 
both panels are listed in Appendix A. The samples were analyzed by flow cytometry immediately 
after the staining was completed.    
Table 2. Antibodies used in each panel 
Target Fluorochrome Manufacture Catalog number 
Panel 1 
CD29 PE/Cy7 BioLegend 102222 
CD45 PE BioLegend 202207 
CD90 Alexa Fluor 488  BioLegend 202506 
Panel 2 
NG2 Alexa Fluor 350 Bioss bs-5829R-A350 
ASMA FITC abcam ab8211 
CD34 PE abcam ab187284 
CD31 Alexa Fluor 647 Bio-Rad MCA1334A647 
    
2.5 Flow cytometry analysis  
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 Samples were analyzed on BD FACSAria™ Fusion with a 100μm nozzle immediately 
following staining. Data was analyzed on FlowJo V10). Each panel of MVF and SVF were 
collected and analyzed separately following the same protocols. Voltage optimizations were 
conducted before every analysis, and compensations were calculated based on freshly made single 
stained control groups. Positive and negative gating thresholds for each channel were determined 
by the FMO controls (Figure 3).  
For both panels, debris and doublets were excluded by gating on area of forward scatter 
(FSC-A) vs. area of side scatter (SSC-A) and FSC-A vs. height of forward scatter (FSC-H). For 
panel 1, the CD29+CD90+ population was gated, from which the MSC (CD29+CD90+CD45-) 
population was identified. For panel 2, The ASMA+NG2- and ASMA+NG2+ populations were 
first gated, and from each population, a CD34 vs. CD31 plot was created. From the ASMA+NG2- 
population, the SMC (ASMA+NG2-CD31-CD34-), mature EC (ASMA-NG2-CD31+CD34-), and 
EC progenitor (ASMA-NG2-CD31+CD34-) populations were identified; from the ASMA+NG2+ 
populations, the pericyte (ASMA+NG2+CD31+) population was identified.  
   




From the FMO controls, the gating thresholds were determined (Figure 3). For SVF panel 
1, Alexa Fluor 488 positive was above 3x103, PE/Cy7 positive was above 2x103, and PE positive 
was above 1x104; for MVF panel 1, Alexa Fluor 488 positive was above 1x104, PE/Cy7 positive 
was above 1x103, and PE positive was above 1x104. For SVF panel 2, FITC positive was above 
3x102, PE positive was above 3x102, Alexa Fluor 647 positive was above3x102, and Alexa Fluor 
350 was above 2x103; for MVF panel 2, FITC positive was above 1x104, PE positive was above 
1x104, Alexa Fluor 647 positive was above1x103, and Alexa Fluor 350 was above 1x104.  
SVF contains a higher percentage of MSC (CD29+CD90+CD45-) than MVF, with SVF 
containing 18.38% MSCs and MVF containing 10.79% MSCs. Figure 4 shows the gating 
sequence. Additionally, SVF has higher percentages of SMC (ASMA+NG2-CD31-CD34-) 
(37.04%) and pericytes (ASMA+NG2+CD31+) (6.59%) than MVF (0.35% and 0.63%, 
respectively). In contrast, mature EC (ASMA-NG2-CD31+CD34-) comprise a higher proportion 
of MVF (23.72%) than SVF (3.15%). Both SVF and MVF have very low content of endothelial 
cell progenitors (ASMA+NG2-CD31+CD34+) (0.17% and 0.12%, respectively).  
  




B   
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D  
Figure 3. FMO control of a) SVF panel 1, b) MVF panel 2, c) SVF panel 2, and d)MVF panel 2. 
 
  





Figure 4. gating sequences of a) SVF and b) MVF panel 1. In SVF, CD29+CD90+CD45- MSC: 18.38%. In MVF, 





Figure 5. gating sequences of a) SVF and b) MVF panel 2. In SVF, ASMA+NG2-CD31-CD34- SMC: 37.04%; ASMA+NG2+CD31+ 
pericytes: 6.39%; ASMA-NG2-CD31+CD34- mature EC: 3.15%; ASMA-NG2-CD31+CD34+ progenitor EC: 0.17%. In MVF, 
ASMA+NG2-CD31-CD34- SMC: 0.35%; ASMA+NG2+CD31+ pericytes: 0.63%; ASMA-NG2-CD31+CD34- mature EC: 23.72%; 
ASMA-NG2-CD31+CD34+ progenitor EC: 0.12%. 
 




It was hypothesized that the difference in the BMP-2 release profiles was due to different 
cellular components of MVF and SVF, and one possible cause of greater BMP-2 release in MVF 
was a higher proportion of MSCs. However, it was observed in this study that SVF has a higher 
percentage of MSC than MVF. Hence, MSC-released BMP-2 causing the difference between the 
SVF and MVF BMP-2 release curves is unlikely. During BMP-2 signaling, BMP-2 receptors are 
internalized upon binding to the ligand, and it has been observed in a study done by Alborzinia 
et.al. that the BMP-2 ligands were also increasingly internalized to the cell center in a time-
depended manner21. Thus, it is possible that the greater BMP-2 release in the MVF group was not 
due to the endogenously secreted BMP-2 by MSCs but rather to feedback mechanisms of greater 
BMP-2 uptake in SVF. However, this does not explain the BMP-2 release profile in the acellular 
group being less than that of the MVF group. Other than the differences in MSC populations, 
SMC, pericyte and mature EC populations are also distinctively different in SVF and MVF. It is 
possible that the BMP-2 release profile is related to the BMP-2 EC interactions. Bouletreau et. al. 
showed in 2002 that upon stimulation with vascular endothelial growth factor (VEGF), BMP-2 
mRNA in EC was upregulated22. Additionally, other studies demonstrated upregulation of BMP-
2 gene expression in vascular EC or upregulation of BMP-2 receptors in cells co-cultured with EC 
under various conditions23-25. VEGF is a key driver of angiogenesis and is expressed by MVF and 
SVF26 It was observed in this study that a higher percentage of mature EC is present in MVF than 
in SVF, which could possibly explain the greater release of BMP-2 in the MVF group.  
A limitation of this study is that adipose-derived cells have significant autofluorescence 
when excited by shorter wavelengths (violet or blue)27. Due to restrictions on minimizing spectrum 
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overlaps, some fluorochromes that are excited at shorter wavelength (such as Alexa Fluor 350, 
Alexa Fluor 488/FITC) were included in our panels. This may have affected the collection of the 
data; some true positive signals may not be detected due to high autofluorescence at the same 









It was originally hypothesized that a higher percentage of MSCs present in MVF than SVF 
caused the greater BMP-2 release profile of MVF-loaded collagen sponges compared to acellular 
or SVF-loaded sponges. This study did not support that hypothesis; however, it demonstrated that 
the SVF and MVF differ in their cellular profiles. The percentage of ECs is much higher in MVF 
(23.72%) compared to SVF (3.15%). This may be the cause of the greater BMP-2 release, as prior 
studies have demonstrated that ECs are capable of producing BMP-2. However, further studies are 
needed to confirm this hypothesis. Future work may include co-loading collagen sponge with 
fluorescently labeled BMP-2 and MVF or SVF to determine whether the excess BMP-2 present in 
the MVF group is released exogenous growth factor or produced (non-labeled) BMP-2. 
Alternatively, BMP-2 mRNA expression in MVF and SVF can be examined, or ECs can be 
transfected to express labeled BMP-2 to investigated the source of the excess BMP-2. 
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APPENDIX A 
CELL PREPARATION PROTOCOLS 
 Obtain MVF and SVF as described in section 2.1 and 2.2. Digest MVF further down to 
single cell level in 3 mL digestion solution on a shaker at 225 rpm at 37 C for 30 minutes. Incubate 
both SVF and MVF in 6mL of 1X RBC lysis buffer for 5 minutes at room temperature. Centrifuge 
at 1,500 rpm for 5 minutes, discard supernatant, and resuspend in 2 mL of 10% FBS in 1X PBS 
(staining buffer). Centrifuge again at 1,500 for 5 minutes and perform cell counting. The final cell 
concentration should be around 1-2 million cells per milliliter.  
 eBioscience OneComp Beads are used for negative makers, such as CD45 and CD34. 
A.1 Cell preparation for panel 1 
 1. Aliquot the cell suspension into 7 1.5 mL Eppendorf tubes with 200 μL in each; 
 2. Add 60 μL of OneComp beads, 138 μL of staining buffer and 2 μL of anti-CD45-PE 
antibody into a seperate1.5 mL Eppendorf tube; 
 3. Add appropriate antibody to the 8 tubes as indicated in the table below (use beads for 
PE single stain control as indicated in step 2) 
 Unstained Single stain controls FMO controls Experimental 
Anti-CD29-
PE/Cy7 
- 2 μL - - - 2 μL 2 μL 2 μL 
Anti-CD45-PE - - 2 μL* - 2 μL - 2 μL 2 μL 
Anti-CD90-
Alexa Fluor 488 
- - - 2 μL 2 μL 2 μL - 2 μL 
Table 3. Panel 1 cell preparation  
*using OneComp beads instead of cells 
 4. Incubate at room temperature for 30 minutes, protected from light; 
 5. Centrifuge at 300 x g for 5 minutes, discard supernatant and resuspend in 200 μL of 
staining buffer; 
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 6. Centrifuge again at 300 x g for 5 minutes, discard supernatant and resuspend in 400 μL 
of staining buffer; 
 7. Transfer to flow tube, analyze immediately. One can resuspend the cells in staining 
buffer containing 1% sodium azide during the last step to allow more time between staining and 
analysis. However, the samples should be analyzed within the same day to ensure optimal results. 
If same day analysis is not possible, sample should be fixed in 100 μL 1% PFA in PBS at 4-degree 
C for 10 minutes. Resuspend in staining buffer. The samples can then be stored in 4-degree fridge 
for up to one week.  
A.2 Cell preparation for panel 2 
 1. Aliquot the cell suspension into 9 1.5 mL Eppendorf tubes with 200 μL in each; 
 2. Add 60 μL of OneComp beads, 138 μL of staining buffer and 2 μL of anti-CD34-PE 
antibody into a seperate1.5 mL Eppendorf tube; 
 3. Add appropriate antibody to the 10 tubes as indicated in the table below (use beads for 
PE single stain control as indicated in step 2). NOTE: although it is listed in the table, no anti-
ASMA-FITC antibody should be added at this point.  
 Unstained Single stain controls FMO controls Experimental 
TUBE# 1 2 3* 4 5 6 7 8 9 10 
Anti-ASMA-FITC - 2 μL - - - - 2 μL 2 μL 2 μL 2 μL 
Anti-CD34-PE - - 2 μL - - 2 μL - 2 μL 2 μL 2 μL 
Anti-CD31-Alexa 
Fluor 647 
- - - 2 μL - 2 μL 2 μL - 2 μL 2 μL 
Anti-NG2-Alexa 
Fluor 350 
- - - - 2 μL 2 μL 2 μL 2 μL - 2 μL 
Table 4. panel 2 cell preparation  
*using OneComp beads instead of cells 
 4. Incubate at room temperature for 30 minutes, protected from light; 
 5. Centrifuge at 300 x g for 5 minutes, discard supernatant and resuspend in 200 μL of 
staining buffer; 
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 6. Centrifuge again at 300 x g for 5 minutes, discard supernatant and resuspend in 100 μL 
of 1% PFA in PBS; 
 7. Incubated at 4-degree C for 10 minutes; 
 8. Centrifuge at 300 x g for 5 minutes, discard supernatant and  
  a. Resuspend tubes 2,7,8,9, and 10 in 100 μL of 0.5% Tween 20 in PBS; 
  b. Resuspend tubes 1,3,4,5, and 6 in 100 μL of staining buffer;  
 9. Incubate at room temperature for 20 minutes; 
 10. Centrifuge all tubes at 300 x g for 5 minutes, discard supernatant and  
  a. Resuspend tubes 2,7,8,9, and 10 in 200 μL of staining buffer; 
  b. Resuspend tubes 1,3,4,5, and 6 in 400 μL of staining buffer, transfer to flow 
tubes; 
 11. Add 2 μL of anti-ASMA-FITC antibody into tubes 2,7,8,9, and 10, incubated at room 
temperature for 30 minutes; 
 12. Centrifuge at 300 x g for 5 minutes, discard supernatant and resuspend in 200 μL of 
staining buffer; 
 13. Centrifuge at 300 x g for 5 minutes, discard supernatant and resuspend in 400 μL of 
staining buffer; 
 14. Transfer to flow tubes, analyze within one week. 
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